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Background/aim: The aim of this study is to evaluate the relationship between serum fatty acid binding protein 4 (FABP4) levels and
carotid intima media thickness (CIMT) in patients with hypothyroidism.
Materials and methods: Forty subclinical hypothyroidism patients, 40 overt hypothyroidism patients, and 40 healthy controls were
enrolled in the study. Blood pressure, body mass index, CIMT, fasting blood sugar, creatine, alanine aminotransferase, lipid parameters,
insulin, free thyroxine, triiodothyronine, thyroid-stimulating hormone (TSH), thyroid peroxidase antibody (anti-TPO), thyroglobulin
antibody (anti-TG), high-sensitivity C-reactive protein (Hs-CRP), and FABP4 levels of all participants were measured.
Results: Serum FABP4 levels were significantly higher in patients with subclinical and overt hypothyroidism than healthy controls
(HCs) (P = 0.044 and P = 0.014, respectively). There was no significant difference in terms of FABP4 levels between patients with
subclinical and overt hypothyroidism (P = 0.641). Serum TSH levels and serum FABP4 levels were positively correlated (r = 0.201,
P = 0.039). CIMT was found to be higher in patients with subclinical and overt hypothyroidism than in HCs (P = 0.042 and P <
0.001, respectively). No correlation was found between CIMT and FABP4 levels (r = 0.038, P = 0.702). There was a positive correlation
between CIMT and TSH, anti-TPO, anti-TG, triglycerides (TG), and total cholesterol levels. It was found that high TG levels were an
independent factor that increased CIMT (r = 0.382, r2 = 0.146).
Conclusion: In patients with subclinical and overt hypothyroidism, the level of FABP4 increases and this increase is correlated with
the increase in TSH level. It is thought that FABP4 does not play a role in atherosclerosis development in patients with hypothyroidism
without metabolic disorder.
Key words: Hypothyroidism, carotid artery intima media thickness, fatty acid binding protein 4, atherosclerosis

1. Introduction
The risk of developing cardiovascular disease (CVD)
increases in patients with hypothyroidism [1]. One of
the factors responsible for CVD in hypothyroidism
is the development of endothelial dysfunction and
reduced response to nitric oxide (NO) [2,3]. Although
it is not clearly known which mechanisms lead to this
condition, symptomatic improvement after thyroid
hormone replacement has been observed [4,5]. In
addition, hypothyroidism also leads to the development of
dyslipidemia, hypercholesterolemia, weight gain, insulin
resistance, coagulation disorders, inflammation, and
diastolic hypertension (HT). The development of these
disorders can also contribute to the incidence of CVD in
hypothyroidism [6–12].

Fatty acid binding protein 4 (FABP4) is a newly
described adipocytokine that is released from adipocytes
and macrophages [13] and is associated with the
development of metabolic syndrome (MetS), insulin
resistance, and increased inflammation. The level of FABP4
has been suggested to be a novel marker that can strongly
predict the risk of MetS development and CVD [14].
Regression in atherosclerotic lesions has been reported
after treatment with a FABP4 inhibitor [15]. FABP4
expression is strongly induced during the differentiation
of adipocytes as well as the differentiation of macrophages
from monocytes. The induction of these cells is regulated
by proinflammatory stimuli [14], which in turn are known
to be regulated by triiodothyronine (T3) [16].
Although both thyroid hormones and FABP4 levels
are associated with CVD development, the relationship
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between the two has not been evaluated to date. The
identification of such a relationship will provide a better
understanding of the mechanism by which hypothyroidism
increases the risk of CVD. Clarifying the etiopathogenesis
of this will guide future studies on targeted molecular
therapy. In the current study, we aimed to evaluate the
effect of FABP4 on the development of CVD in patients
with hypothyroidism.
2. Materials and methods
This study was approved by the local ethics committee. All
patients to be included in the study were informed verbally
and in writing about the research and informed consent
forms were obtained from those who agreed to participate
in the study.
2.1. Selection of the subjects to be included in the study
The study group consisted of 40 patients between the
ages of 18 and 65 years (3 males, 37 females) who were
admitted to our clinic with subclinical hypothyroidism
(SH), 40 patients (9 males, 31 females) between the ages
of 18 and 65 years who were admitted to our clinic with
overt hypothyroidism (OH), and 40 people (3 males, 37
females) with no systemic disease who formed the healthy
control (HC) group. The patients with SH had thyroidstimulating hormone (TSH) levels greater than 4.94 µIU/L
with normal free thyroxine (fT4) levels. Patients with OH
had TSH of >4.94 and low fT4 levels.
Patients with inflammatory diseases (acute infectious
diseases, malignancies, inflammatory rheumatic diseases);
pregnant patients; those with chronic kidney disease,
diabetes mellitus, MetS, HT, and acute or chronic
liver disease; and patients using glucocorticoids and
nonsteroidal antiinflammatory drugs were excluded from
the study.
2.2. Anthropometric and blood pressure measurements
Blood pressure measurements were carried out for both
brachial arteries after the patient had rested for at least 5
min in sitting position prior to the measurements. Body
weight and height measurements of all participants were
recorded and body mass index (BMI) was calculated by
dividing the body weight by the square of the height (kg/
m2).
2.3. Biochemical analysis
Fasting blood glucose (FBG), creatine, alanine
aminotransferase (ALT), high-density lipoproteincholesterol (HDL-C), triglycerides (TG), low-density
lipoprotein-cholesterol (LDL-C), total cholesterol (TC),
free triiodothyronine (fT3), free thyroxin (fT4), thyroidstimulating hormone (TSH), and insulin levels were
measured by using the electrochemiluminescence method
with an Abbot Aeroset chemical commercial kit (Abbot
Park, IL, USA). Insulin resistance was calculated by using
the homeostasis model assessment (HOMA = (FBG ×

insulin)/405)) [17]. Antithyroid peroxidase (anti-TPO)
and antithyroglobulin (anti-TG) levels of the patients
with SH and OH were also measured. FABP4 and highsensitivity C-reactive protein (Hs-CRP) levels were
measured by Biosensitive DPC (USA) brand Immulatory
2000 device using compatible commercial kits.
2.4. Carotid intima media thickness measurement
The carotid intima media thickness (CIMT) of each subject
was measured by using a 7.5–13.5 MHz multifrequency
linear array probe with B-mode ultrasonography (USG)
and duplex Doppler examination (Shimadzu, Japan). All
USG examinations were performed by the same operator
in a quiet environment after each individual had rested
for approximately 15 min. For carotid artery imaging, it
was ensured that the neck muscles were relaxed and the
patient was lying in a supine position with an angle of
approximately 20° towards the neck. Measurements were
made from 3 different points 1 cm distal of the right and left
anterior carotid artery; only the posterior (distant) wall was
evaluated and the intima media thickness measurements
were carried out. The average of two measurements was
accepted as the mean CIMT.
2.5. Statistical analysis
The Shapiro–Wilk test was used to determine whether
continuous variables were normally distributed. The
Kruskal–Wallis test and Dunn multiple comparison
test were used to compare more than two independent
groups. The Student t-test was used for the comparison
of variables with normal distribution (HDL-C, LDL-C),
while the Mann–Whitney U test was used for variables
that did not have a normal distribution. Categorical data
were compared by chi-square test (sex). The relationships
between CIMT, FABP4, Hs-CRP, thyroid function tests
(TSH, fT3, fT4, anti-TPO, anti-TG), and metabolic
parameters were evaluated by Spearman correlation
analysis. The effect of BMI, fT3, and TSH on LDL-C levels
was evaluated by multiple regression analysis. Multiple
regression analysis was also used to evaluate the effect
of BMI and Hs-CRP on FABP4 level and to evaluate the
effects of TSH, anti-TPO, TG, and FABP4 on CIMT. SPSS
22.0 for Windows was used for statistical analysis and P <
0.05 was considered statistically significant.
3. Results
3.1. Demographic, clinical, and biochemical
characteristics of participants
Demographic, clinical, and biochemical characteristics
of the study groups are shown in Table 1. There was no
statistically significant difference in age or sex between the
groups (P = 0.198 and P = 0.064, respectively). There was
no significant difference between the groups in the levels
of creatinine, ALT, HDL-C, F, and HOMA (P = 0.180, P

1491

TAN et al. / Turk J Med Sci
Table 1. Demographic, clinical, and biochemical characteristics of study groups.
HC

SH

OH

P (HC-SH) P (HC-OH) P (SH-OH)

Age (years)

28.0 ± 19.0

32.0 ± 27.0

36.0 ± 12.0

0.312

0.067

0.485

Body weight (kg)

56 ± 7

59 ± 15

64.5 ± 14

0.096

<0.001

0.035

BMI (kg/m )

21.39 ± 3.52 23.67 ± 5.37

24.4 ± 4.47

0.060

<0.001

0.127

FBG (mg/dL)

94.5 ± 10.0

95.00 ± 10.0

91.0 ± 17.0

0.383

0.593

0.258

Insulin (mU/L)

9.85 ± 4.8

8.0 ± 3.5

8.07 ± 5.0

0.438

0.131

0.228

HOMA

2.12 ± 1.42

1.99 ± 0.9

1.81 ± 1.36

0.535

0.183

0.315

Creatinine (mg/dL)

0.8 ± 0.18

0.82 ± 0.13

0.8 ± 0.2

0.119

0.829

0.1

ALT (mg/dL)

15.0 ± 9.6

14.0 ± 8.8

17.0 ± 9.0

0.927

0.124

0.056

TC (mg/dL)

187.0 ± 51.5 192.0 ± 60.25 198.0 ± 56.5 0.362

0.012

0.177

TG (mg/dL)

79.0 ± 24.0

96.0 ± 75.0

109.5 ± 129 0.004

<0.001

0.101

HDL-C (mg/dL)*

57.0 ± 22.0

54.0 ± 18.0

56.5 ± 22.0

0.598

0.731

1.0

LDL-C (mg/dL)*

109.0 ± 48.0 113.5 ± 40.0

124.5 ± 76.0 0.866

0.045

0.109

fT3 (pg/mL)

3.35 ± 0.6

3.3 ± 0.52

3.0 ± 0.95

0.650

<0.001

<0.001

fT4 (ng/dL)

0.8 ± 0.2

0.8 ± 0.22

0.4 ± 0.3

0.353

<0.001

<0.001

TSH (µIU/mL)

2.12 ± 1.42

1.99 ± 0.9

1.81 ± 1.36

<0.001

<0.001

<0.001

Anti-TPO (U/mL)

2.0 ± 5.0

87.0 ± 381.1

18.0 ± 442.0 <0.001

0.012

0.522

Anti-TG (U/mL)

0.6 ± 2.3

4.1 ± 34.6

0.75 ± 35.8

0.002

0.198

0.161

FABP4 (ng/mL)

5.22 ± 3.29

6.67 ± 6.58

7.03 ± 7.26

0.044

0.014

0.641

Hs-CRP (mg/L)

2.0 ± 3.38

2.7 ± 4.15

3.65 ± 2.85

1.51

0.096

0.491

CIMT (mm)

0.5 ± 0.16

0.5 ± 0.27

0.6 ± 0.2

0.042

<0.001

0.157

2

Healthy control, HC; subclinical hypothyroidism, SH; overt hypothyroidism, OH; fasting blood glucose, FBG;
alanine aminotransferase, ALT; total cholesterol, TC; triglyceride, TG; high-density lipoprotein-cholesterol, HDL-C;
low-density lipoprotein-cholesterol, LDL-C; free triiodothyronine, fT3; free thyroxine, fT4; thyroid-stimulating
hormone, TSH; antithyroid peroxidase antibodies, Anti-TPO; antithyroglobulin antibodies, Anti-TG; fatty acid
binding protein 4, FABP4; high-sensitivity C-reactive protein, Hs-CRP; carotid intima media thickness, CIMT.

= 0.138, P = 0.900, P = 0.187, P = 0.463, and P = 0.349,
respectively). BMI was significantly higher in patients
with OH than the healthy controls (P < 0.001). Although
BMI was higher in patients with SH compared to healthy
controls, this was not statistically significant by a borderline
difference (P = 0.06). There was no statistically significant
difference in the BMIs of patients with SH and OH.
In patients with OH, the serum fT3 and fT4 levels were
lower than in patients with SH or in HCs, whereas TSH
levels were found to be high (P < 0.001 for each comparison).
TSH levels were significantly higher in patients with SH
than HCs (P < 0.001). There was no significant difference
in fT3 and fT4 levels between patients with SH and HCs (P
= 0.650 and P = 0.353, respectively). Anti-TPO and antiTG levels were significantly higher in patients with SH
than HCs (P < 0.001 and P = 0.002, respectively). There
was no statistically significant difference in anti-TG and
anti-TPO levels between patients with SH and OH (P =
0.522 and P = 0.16, respectively).
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TG, LDL-C, and TC levels were significantly higher in
patients with OH than HCs (P < 0.001, P = 0.045, and P
= 0.012, respectively). TG levels were significantly higher
in patients with SH when compared to HCs (P = 0.004).
There was no significant difference in lipid levels between
SH and OH patients (P > 0.05). Although the Hs-CRP
level was higher in patients with SH and OH compared to
the HC group, it was not statistically significant (P > 0.05).
The FABP4 levels of the groups are shown in Figure
1. The FABP4 levels were significantly higher in patients
with SH and OH than the HC group (P = 0.044 and P =
0.014, respectively). There was no significant difference in
FABP4 levels between SH and OH patients (P = 0.641).
In the Spearman correlation analysis, serum FABP4 level
was positively correlated with TSH, BMI, and Hs-CRP (r
= 0.201, P = 0.039; r = 0.201, P = 0.039; and r = 0.354, P <
0.001, respectively). The correlation graph between FABP4
and Hs-CRP is shown in Figure 2. The independent
variables affecting the FABP4 level were evaluated by
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Figure 1: FABP4 levels of groups

detected between TG level and fT4 (r = 0.291, P = 0.002;
r = –0.282, P = 0.003, respectively). Moreover, a positive
correlation was detected between the levels of TC and TSH
and a negative correlation was found between fT3 and TC
(r = 0.210, P = 0.028; r = –0.282, P = 0.003).
3.2. Carotid intima media thicknesses of the participants
CIMT was higher in patients with SH and OH compared
to the HC group (P = 0.042 and P < 0.001, respectively).
The CIMT values of the patients are shown in Figure
3. Spearman correlation analysis indicated a positive
correlation between CIMT and TSH, anti-TPO, anti-TG,
TG, and TC levels in patients (r = 0.265, P = 0.007; r =
0.251, P = 0.014; r = 0.225, P = 0.028; r = 0.373, P < 0.001;
r = 0.252, P = 0.012). No correlation was found between
CIMT and FABP4 levels in patients (r = 0.038, P = 0.702).
The independent variables affecting CIMT were evaluated
by multiple regression analysis. The TG level was found to
be an independent factor associated with an increase in
CIMT (Table 2).

119

CIMT (mm)

1.00

0.80

0.60

0.40
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SH
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Figure 2. Carotid Intima Media Thickness of Groups

multiple regression analysis. BMI and Hs-CRP were shown
to be correlated with 34.4% of the change in FABP4 level (r
= 0.586, r2 = 0.344).
The relationships between BMI, metabolic parameters
(FBG, insulin, TG, LDL-C, HDL-C, TG, TC), and the
parameters related to thyroid function (TSH, fT4, fT3, antiTPO, anti-TG) were evaluated by Spearman correlation
analysis. There was a positive correlation between BMI
and LDL-C, TSH, and TC and a negative correlation with
fT4 (r = 0.270, P = 0.007; r = 0.311, P = 0.001; r = 0.258,
P = 0.01; r = –0.280, P = 0.004). In addition, there was
a negative correlation between LDL-C level and fT3 (r =
–0.256, P = 0.007). A positive correlation was detected
between TG level and TSH and a negative correlation was

Figure 3. Correlation Between FABP4 and hs-CRP Levels

Table 2. Multiple regression analysis of
variables affecting CIMT.
β coefficients P-value
TSH

0.139

0.172

Anti-TPO

0.166

0.093

TG

0.245

0.016

FABP4

0.053

0.601

Thyroid-stimulating hormone, TSH;
antithyroid peroxidase antibodies, AntiTPO; fatty acid binding protein 4, FABP4.
r: 0.382, r2: 0.146
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4. Discussion
The most important findings of this study were that
CIMT was increased in patients with subclinical and overt
hypothyroidism and that the serum level of TG was found
to be an independent factor associated with this increase
in CIMT. In addition, serum FABP4 levels were found to
be increased in patients with SH and OH, but this increase
was not correlated with the increase in CIMT.
Increase or decrease in thyroid hormone levels can
cause various adverse effects on the cardiovascular system
[18]. The etiology for increased risk of CVD in hypothyroid
patients includes dyslipidemia, hypercholesterolemia,
insulin resistance, endothelial dysfunction, coagulation
disorders, inflammation, diastolic HT, and weight gain
[18–20].
It is known that elevation of LDL-C has a strong effect
in increasing the risk of CVD [21]. In the Helsinki Heart
study, even a 7% decrease in LDL-C level was shown
to reduce the incidence of CVD by 15% [22]. The most
common lipid abnormality in OH is an increase in LDL.
Mechanistically, a decrease in LDL receptor level and
LDL catabolism has been proposed [21–23]. In addition,
elevations of TG and TC are also seen in OH [23]. In
the current study, TG, LDL-C, and TC levels were found
to be high in patients with OH, which corroborated
the published data (P < 0.001, P = 0.045, and P = 0.012,
respectively). There was also a positive correlation between
TC and the levels of LDL-C and TSH (P = 0.001, P = 0.01,
respectively).
Data on lipid alteration in SH are controversial. In
the Whickham study (2779 patients, men and women
over 18 years of age), no relationship between SH and
hyperlipidemia was found; however, the Rotterdam
and Nagasaki studies indicated that the TC levels were
increased in women with SH [24–26]. Saric et al. reported
that TG and LDL levels were higher in patients with SH
[27].
In a metaanalysis by Abreu et al., the levels of TC and
LDL-C were found to be increased in patients with SH
and this was correlated with the increase in TSH. These
authors also observed a correlation between TG and TSH
levels [28]. In the current study, TG level was found to be
significantly higher in subjects with SH compared to HCs
(P = 0.004). Differences between the results of various
studies may be due to the fact that different cut-off points
were used for the definition of SH as well as differences
in sex, ethnicity, age, and duration of hypothyroidism in
the patient cohorts. Elderly patients are known to be more
affected by thyroid dysfunction. In a cross-sectional study
with 30,656 participants aged 70–79 years, it was shown
that lipid levels were affected in patients whose TSH levels
were within the normal range [29]. In a study of 2308
participants by Tognimi et al., a significant impairment in
lipid levels was demonstrated in patients with both SH and
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OH who were older than 65 years [30]. In the current study,
the modest effect on lipid levels can be explained by the
fact that the patient cohort was relatively young; moreover,
these patients did not have any metabolic disorders and
their BMIs were within the normal range.
It is well established that a strong relationship
exists between circulating inflammatory markers and
cardiovascular events. Hs-CRP is commonly used as
an inflammatory marker [31]. Serum Hs-CRP levels are
known to vary widely in patients with hypothyroidism
[12,32,33]. Bell et al. reported that Hs-CRP levels remained
unchanged in SH patients [34]. Tuzcu et al. reported that
the Hs-CRP level was higher in SH patients and this
was also correlated with fasting insulin [35]. Peixoto et
al. reported from a study of 12,284 volunteers (11,589
euthyroid, 695 SH) that there was no correlation between
TSH and Hs-CRP levels in the SH group and obesity and
insulin resistance were the factors responsible for the
increase in Hs-CRP in SH patients [11]. In the current
study, we did not observe any significant difference in HsCRP levels in the participants with OH and SH (P > 0.05).
Additionally, no statistically significant differences were
observed for BMI, insulin, and FBG levels between the
groups (P > 0.05). We surmised that the lack of difference
in Hs-CRP levels between OH and SH groups could be due
to the absence of any metabolic disorder in these patients,
which would lead to an increase in inflammation.
Elevation of serum FABP4 is a newly identified risk
marker for predicting the development of MetS and CVD
[36]. In many studies FABP4 has been shown to play a
role in the development of atherosclerosis by activating an
inflammatory response through inhibition of endothelial
nitric oxide synthetase in smooth muscle cells [37–39].
Both increase in serum FABP4 level and the presence of
hypothyroidism have roles in the development of MetS,
dyslipidemia, insulin resistance, and CVD [6,8,40–45].
However, the relationship between TSH level and FABP4
level has not been evaluated to date, which we aimed to
do in the current study. The FABP4 level was higher in
patients with SH and OH compared to HCs (P = 0.044 and
P = 0.014, respectively). There was a positive correlation
between FABP4 and TSH levels (P = 0.039). However,
when multiple regression analysis was performed, we
observed that the increase in FABP4 levels could be
attributed to increased BMI and inflammation. Although
the mean BMI and Hs-CRP levels of the three groups were
within the normal ranges, we hypothesized that alterations
within the normal range could potentially affect the levels
of FABP4. These findings suggest that the reason for the
increase in FABP4 levels in hypothyroid patients could be
an increase in body weight and inflammation.
Several studies have shown that hypothyroidism
increases the risk for the development of CVD [22,46,47].
In a retrospective study by Selmer et al. with 563,700
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participants, the risk of CVD and mortality was found
to be increased in people with both OH and SH [48]. In
addition, Moon et al. carried out a metaanalysis of 35
cohort studies involving 555,530 participants and reported
that CVD risk was increased in patients with SH [49].
CIMT measurement has been used in several studies as
an early and noninvasive indicator of atherosclerosis [50].
In the current study, CIMT was also used as an indicator
of atherosclerosis. It has already been shown that CIMT
increases in patients with SH and OH [51]. In the current
study, we observed that the increases in CIMT were
coupled with increases in TSH levels in patients with
both SH and OH. In a multiple regression analysis, it
was determined that the independent factor contributing
to the increase in CIMT was an increase in TG levels.
In addition, no correlation between FABP4 level and
CIMT was observed, most likely due to the normal BMIs
and absence of any metabolic diseases in the patients.
Accordingly, we suggest that there is no effect of FABP4

level on CIMT in hypothyroid patients who do not have
any underlying metabolic disorders.
This study has some limitations due to being a crosssectional study. It would be valuable to demonstrate the
changes in thyroid function tests, lipids, and FABP4 levels
and the correlations between them after treatment with
levothyroxine in patients.
In conclusion, in the current study, an increase
in CIMT was observed in patients with SH and OH.
In all patients with hypothyroidism, CIMT was more
pronounced in those patients with higher TSH levels. In
hypothyroid individuals without any metabolic disorders,
the independent factor for increasing CIMT was elevation
of TG and no effect of FABP4 could be ascertained.
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